乐观
$180.85
情景价格
$124.260
+4.125 (+3.32%)收盘时
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.
Aptargroup Inc is currently priced at $120.38, which is below the average analyst price target of $150, indicating potential upside. However, the stock has an RSI of 37.32, suggesting it is oversold, but the recent performance shows a 1-year decline of 7.56%, indicating ongoing challenges. The main risk is the company's declining gross margin, which fell to 27.85% in Q2 2026, down from 30.89% in Q4 2024, reflecting pressures on profitability.
UBS
$135
2026-10-09
UBS
2026-10-09
目标价
$135
BofA
$154
2026-10-06
BofA
2026-10-06
目标价
$154
BofA
$172
2026-07-31
BofA
2026-07-31
目标价
$172
Raymond James
$160
2026-07-15
Raymond James
2026-07-15
目标价
$160
BofA
$173
2026-07-14
BofA
2026-07-14
目标价
$173
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Aptar Pharma Secures CE Mark for LuerVax® Device

Latest Wall Street Rating Updates

Aptar Partners with MGH to Advance Nose-to-Brain Drug Delivery

AptarGroup Shares Fall Below 200-Day Moving Average

West Pharmaceutical Services Positioned for Growth Amid Booming Injectable Market
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).
Aptargroup Inc is currently priced at $120.38, which is below the average analyst price target of $150, indicating potential upside. However, the stock has an RSI of 37.32, suggesting it is oversold, but the recent performance shows a 1-year decline of 7.56%, indicating ongoing challenges. The main risk is the company's declining gross margin, which fell to 27.85% in Q2 2026, down from 30.89% in Q4 2024, reflecting pressures on profitability.
9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。